FRC
FRC Logo
Community
Sign InGet Access

Connect With Us

Stay updated with our latest research and insights

Fundamental Research Corp Logo

Highly ranked equity research firm providing institutional grade tools and analysis to all investors worldwide. Trusted by global investors for over 20+ years.

20+ Years
Rate us on TrustpilotLeave a review

Policies

  • Privacy Policy
  • Terms of Service
  • Disclaimer

Company

  • About Us
  • Our Team
  • Contact Us
  • Leave a Review

Resources

  • Videos
  • Research Reports
  • Community
  • FAQ
  • How to use the site

Browse

  • Stock Directory
  • Stock Screener
  • Market Intel Weekly
  • Report Archive

Trackers

  • Congress Trading
  • Senate Trading
  • Congress Net Worth
  • Markets

© 2026 Fundamental Research Corp. All Rights Reserved.

Professional investment research since 2003

Home
Strategies
Intel
Analysis
Community
Company ProfileSeaport Therapeutics, Inc. Common Stock
  • Company Overview
  • Financial Data
  • Peer Comparison
  • Ownership & News
  • Discussion
SPTX
Seaport Therapeutics, Inc. Common Stock Stock AnalysisComprehensive stock analysis for Seaport Therapeutics, Inc. Common Stock (SPTX) including live price, Snowflake performance metrics, financial statements, and investment research.Stock AnalysisSPTX
SPTX
Seaport Therapeutics, Inc. Common Stock
  • Company Overview
  • Financial Data
  • Peer Comparison
  • Ownership & News
  • Discussion
SPTX
  1. Home
  2. Stocks
  3. Seaport Therapeutics, Inc. Common Stock

Seaport Therapeutics, Inc. Common Stock

🇺🇸SPTX•NASDAQ

Seaport Therapeutics, Inc. Common Stock

🇺🇸SPTX•NASDAQ
Market cap
$966.23M

Your view on SPTX

Mkt Cap
$966.23M
Your view
Company Overview

Overview

What the company does, where it operates, and who runs it.

About Seaport Therapeutics, Inc. Common Stock

Industry
Biotechnology
Sector
Healthcare
CEO
Daphne Zohar
Headquarters
101 Seaport Blvd., Boston, MA, US
Industry
Biotechnology
Sector
Healthcare
CEO
Daphne Zohar
Headquarters
101 Seaport Blvd., Boston, MA, US
Description

Seaport Therapeutics, Inc. is a developing biopharmaceutical enterprise currently undergoing clinical trials, focused on creating groundbreaking treatments for neuropsychiatric conditions. The company is primarily engaged in tackling disorders like depression and anxiety, utilizing its unique Glyph technology.

This exclusive platform is engineered to allow for oral administration of drugs, circumventing initial metabolic processing in the liver, and thereby reducing the risk of liver enzyme elevations, hepatotoxicity, and other potential adverse reactions.

Every therapeutic agent in their pipeline incorporates this advanced platform, with all research and development efforts exclusively dedicated to neuropsychiatric applications.

Founded in 2024 and situated in Boston, Massachusetts, the company connects with medical professionals and influential experts across the healthcare and neuropsychiatric sectors.

Financial Data

Stock Data

Price chart, volume, and trading data.

Financial Ratios

Profitability, returns, valuation, and leverage ratios.

About this section

Valuation, profitability, liquidity and leverage ratios for Seaport Therapeutics, Inc. Common Stock. Starting points for Seaport Therapeutics, Inc. Common Stock: EPS -$2.59, beta 1.13 — an Biotechnology name. P/E, P/B, EV/EBITDA, margins, return on equity, current ratio and debt coverage, each shown against the company's own history.

Earnings Analysis

EPS history, beat rate, and upcoming earnings reports.

About this section

Reported vs. expected earnings history for Seaport Therapeutics, Inc. Common Stock. Trailing twelve-month EPS for Seaport Therapeutics, Inc. Common Stock stands at -$2.59. EPS surprises by quarter, revenue against estimates, and the upcoming reporting date.

Wall Street Analyst Estimates

Analysts' price targets, ratings, and revenue and EPS estimates.

Wall Street analysts· not FRC research
Nov 22, 2026
Analysts' target$38.50average of 4 firms, last 12 months
Current price—

Buy

Targets, low to high

$38.50

Low $28.00

Middle $38.00

High $50.00

Analyst ratings

2 ratings
  • Strong Buy0
  • Buy2
  • Hold0
  • Sell0
  • Strong Sell0
More →

Earnings per share estimates

Per shareThis quarterDec 2026Next quarterMar 2027This yearYear to Dec 2026Next yearYear to Dec 2027
Average estimate−$0.56−$0.57−$4.13−$2.45
Lowest estimate−$0.66−$0.61−$4.89−$3.06
Highest estimate−$0.51−$0.54−$3.79−$2.09
Number of analysts5466
A year ago—−$5.50−$1.401—
Growth vs a year ago—+89.7%——

1The year-ago figure includes one-time items, so growth is not shown.

Revenue estimates

TotalThis quarterDec 2026Next quarterMar 2027This yearYear to Dec 2026Next yearYear to Dec 2027
Average estimate$0.00$0.00$0.00$0.00
Lowest estimate$0.00$0.00$0.00$0.00
Highest estimate$0.00$0.00$0.00$0.00
Number of analysts0000
A year ago—$0.00$0.00—
Growth vs a year ago————
Recent rating and target changes (12)

Financial Statements

Income statement, balance sheet, and cash flow statements.

About this section

Income statement, balance sheet and cash flow history for Seaport Therapeutics, Inc. Common Stock. Seaport Therapeutics, Inc. Common Stock has reported as a listed company since 2026. Annual and quarterly filings with period-over-period comparison, so you can trace how revenue, margins and cash generation have moved.

Peer Comparison

Comparables

List of peer companies in the same industry.

Peers, the industry, and the funds that hold SPTX20 companies · 8 funds
Compare SPTX with its peers, side by sidePremiumRatios, margins, valuation and leverage of the peers below — one table, one glance.Open Comparable Analysis
Peer companies
TickerTypeCompanySectorIndustryMkt cap
CTNMContineum Therapeutics, Inc. Class A Common StockHealthcareBiotechnology$306.9M
GHRSGH Research PLCHealthcareBiotechnology$1.2B
KTTAPasithea Therapeutics Corp.HealthcareBiotechnology$17.6M
LBRXLB Pharmaceuticals Inc Common StockHealthcareBiotechnology$1.3B
MPLTMapLight Therapeutics, Inc.HealthcareBiotechnology$253.2M
NMRANeumora Therapeutics, Inc. Common StockHealthcareBiotechnology$63.0M
QNTMQuantum BioPharma Ltd.HealthcareBiotechnology$8.3M
RAPPRapport Therapeutics, Inc. Common StockHealthcareBiotechnology$1.1B
More Biotechnology companies
TickerTypeCompanySectorExchangeMkt cap
PDSBPDS Biotechnology CorporationHealthcareNASDAQ$43.4M
PEPGPepGen Inc.HealthcareNASDAQ$261.8M
PFNDPathfinder Cell Therapy, Inc.HealthcareOTC$66,716
PGENPrecigen, Inc.HealthcareNASDAQ$1.5B
PHARPharming Group N.V.HealthcareNASDAQ$814.5M
PHATPhathom Pharmaceuticals, Inc.HealthcareNASDAQ$378.8M
PHGUFPharming Group N.V.HealthcareOTC$1.1B
PHIOPhio Pharmaceuticals Corp.HealthcareNASDAQ$7.8M
PHMMFPharma Mar, S.A.HealthcareOTC$1.5B
PHRM.CNPharmaTher Holdings Ltd.HealthcareCNQ$9.1M
PHRRFPharmaTher Holdings Ltd.HealthcareOTC$5.3M
PHVSPharvaris N.V.HealthcareNASDAQ$2.2B
ETFs holding Seaport Therapeutics, Inc. Common Stock
TickerFundFund assets% of the fund
IWMiShares Russell 2000 ETF$76.6B in assets0.01%
VTIVanguard Total Stock Market ETF$689.2B in assets0.00%
VXFVanguard Extended Market ETF$30.2B in assets0.00%
PSILAdvisorShares Psychedelics ETF$42M in assets5.43%
IWCiShares Micro-Cap ETF$1.2B in assets0.07%
VTWGVanguard Russell 2000 Growth ETF$1.4B in assets0.01%
RSSLGlobal X - Russell 2000 ETF$1.4B in assets0.01%
IWNiShares Russell 2000 Value ETF$13.9B in assets0.01%

Largest holders first, then the funds most concentrated in SPTX.

Open Comparable Analysis
Ownership & News

Institutional Ownership

Which funds and firms own the stock.

About this section

Which institutions hold Seaport Therapeutics, Inc. Common Stock, and how their positions are changing. At a $966.2M market value, institutional positions materially move Seaport Therapeutics, Inc. Common Stock's register. Top holders, position sizes, and quarter-over-quarter accumulation or distribution from regulatory filings.

Insider Trading

Recent buying and selling by company executives.

About this section

Buying and selling by Seaport Therapeutics, Inc. Common Stock executives and directors. Shares of Seaport Therapeutics, Inc. Common Stock have traded between $14.85 and $24.48 over the past 52 weeks — context for the timing of the transactions below. Insider transactions as disclosed to regulators, with role, size and date — the clearest read on how the people running the company are positioned.

News

Latest headlines and market coverage.

About this section

Latest headlines and company announcements for Seaport Therapeutics, Inc. Common Stock. Coverage tracks Seaport Therapeutics, Inc. Common Stock within Biotechnology (Healthcare). Press releases and market coverage, newest first.

Discussion

Comments

Comments and replies from FRC members about this company.

No comments yet

Be the first to ask a question or say what you make of Seaport Therapeutics, Inc. Common Stock.

SPTX AnalysisFair
Past
1
Growth
2
Health
5
Profit
1
Value
1